Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report issued on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, Maxim Group upgraded shares of Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research note on Thursday, July 11th.

Brainstorm Cell Therapeutics Price Performance

Shares of Brainstorm Cell Therapeutics stock opened at $2.64 on Tuesday. Brainstorm Cell Therapeutics has a 1-year low of $2.01 and a 1-year high of $11.89. The company’s fifty day simple moving average is $0.40 and its 200-day simple moving average is $0.45. The stock has a market capitalization of $185.01 million, a PE ratio of -8.25 and a beta of 0.35.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). During the same quarter in the previous year, the firm posted ($0.27) EPS. As a group, research analysts anticipate that Brainstorm Cell Therapeutics will post -0.19 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics as of its most recent SEC filing. 14.33% of the stock is currently owned by institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.